sirolimus + rivaroxaban + argatroban

A combination of sirolimus, rivaroxaban, and argatroban represents a regimen consisting of three pharmacologically distinct agents: - **Sirolimus**: an immunosuppressant and mTOR inhibitor that suppresses T-cell proliferation and antibody production by inhibiting the mammalian target of rapamycin (mTOR) pathway, used mainly for organ rejection prophylaxis, certain vascular anomalies, and rare tumors[1][2][4][6][8][10]. - **Rivaroxaban**: a direct factor Xa inhibitor anticoagulant that prevents thrombin generation and fibrin clot formation, commonly used for prevention and treatment of thromboembolic disorders[3]. - **Argatroban**: a direct thrombin inhibitor anticoagulant, often used in patients with heparin-induced thrombocytopenia, which inhibits thrombin-mediated effects including fibrin formation, activation of coagulation cofactors, and platelet aggregation[7]. These drugs have different primary indications, but combinations (notably of sirolimus + rivaroxaban, and argatroban + sirolimus) have been reported in clinical situations such as complicated vascular malformations or catastrophic antiphospholipid syndrome, though there is no established single product or widespread approved clinical protocol combining all three agents[3][5].